Persistent Asset Partners’s Nektar Therapeutics NKTR Stock Holding History

Persistent Asset Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$522K	Buy	7,481 +1,661	+29%	+$122K	0.16%	107
2026 Q1	$419K	Buy	+5,820	New	+$331K	0.16%	124
2025 Q4	–	Sell	-17,270	Closed	-$983K	–	419
2025 Q3	$983K	Buy	+17,270	New	+$572K	0.68%	49
2025 Q1	–	Sell	-11,105	Closed	-$145K	–	200
2024 Q4	$138K	Buy	+11,105	New	+$196K	0.11%	95

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Persistent Asset Partners's NKTR Position: Q2 2026 in Review

Persistent Asset Partners increased its Nektar Therapeutics (NKTR) stake by 29% in Q2 2026, buying an estimated $122K and bringing the position to 7,481 shares worth $522K. The position accounts for 0.16% of the portfolio, ranked #107.

Persistent Asset Partners first reported a position in NKTR in Q4 2024 and has held it in 4 quarters since. The position peaked at $983K in Q3 2025. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Persistent Asset Partners held 7,481 shares of Nektar Therapeutics worth $522K as of Q2 2026.
Persistent Asset Partners bought 1,661 Nektar Therapeutics shares in Q2 2026, an estimated $122K.
Nektar Therapeutics made up 0.16% of Persistent Asset Partners's portfolio in Q2 2026, its #107 holding.
Persistent Asset Partners first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 4 quarters since.
Persistent Asset Partners's Nektar Therapeutics position peaked at $983K in Q3 2025.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.